<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933984</url>
  </required_header>
  <id_info>
    <org_study_id>102-CCH-IRP-017</org_study_id>
    <nct_id>NCT01933984</nct_id>
  </id_info>
  <brief_title>Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients</brief_title>
  <official_title>Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin-hwar Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether individualized dosing schedule of inhaled bronchodilator is more
      effective than fixed dosing in reducing airway resistance of intubated COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      *Study Design

        -  This is an open-label, randomized controlled study comparing individualized versus fixed
           bronchodilator dosing schedule for patients with COPD with acute respiratory failure.

           *Patients Enrollment

        -  We will collect 100 patients just admitted to the intensive care unit of Changhua
           Christian Hospital (Changhua, Taiwan) due to COPD with acute respiratory failure.All
           participants will be randomly assigned to either group according to a computer-generated
           allocation sequence in block size of 4 patients.

           *Airway Resistance (Raw) Determination

        -  Enrolled patients will be ventilated by either AVEA (CareFusion, Yorba Linda, CA,
           USA),e500 (Newport Medical Instrument Inc. CA, USA) or Eivta 4 (Drager) ventilator. When
           evaluating Raw, the ventilator settings will be transiently switched to volume control
           mode with fixed tidal volume (500 ml) and constant flow (with a rate of 60 L/min).
           Plateau pressure is measured by manually controlled end-inspiratory pause12. Every
           effort will be exercised to avoid excessive airway secretion or patient agitation during
           measurement. Each measurement will be repeated three times with an interval of at lease
           1 minute and calculate their average. Raw will be calculated by an equation of (peak
           inspiratory pressure - plateau pressure)/flow. After each measurement, the ventilator
           will soon be reverted to its usual settings. Raw will be routinely determined every 8
           hours for 28 days if the ventilator is not discontinued.

           *Technique of Metered Dose Inhaler (MDI) administration through endotracheal tube

        -  The technique basically follows the recommendation of Dhand and Guntur. Airway
           secretions should be sucked out before drug administration. Heat moisture exchanger, but
           not humidifier, is removed. After shaking and warming MDI to hand temperature, the
           canister is connected to an AeroChamber HC MV spacer (Trudell Medical International,
           London, Canada) placed in the inspiratory limb of ventilator circuit 15 cm away from the
           endotracheal tube. Actuation is synchronized with the initiation of inspiration. Each
           actuation is at least 15 second apart.

           *Personal Target Raw Determination

        -  The target Raw of each patient should be determined within 72 hours after their
           admission to intensive care unit. After confirming no inhaled bronchodilator given in
           preceding 2 hours (for fenoterol) or 12 hours (for salmeterol/fluticasone), we will
           deliver 3 consecutive doses of 4 puffs, 8 puffs and 16 puffs of fenoterol MDI (100
           mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15
           minutes apart. The Raw measured 15 minutes later is assigned as this patient's personal
           target Raw.

           *Bronchodilator Delivery Schedule

        -  Each patient will routinely receive 4 puffs of 25 mcg salmeterol /250 mcg fluticasone
           (Seretide Evohaler 250; GlaxoSmithKline Inc. Evreux, France) every 12 hours until the
           discontinuation of ventilator. Each patient will also routinely receive 1 vial of
           Combivent (ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg) every 6 hours and be
           injected with intravenous methylprednisolone 40mg every 8 hours in the initial 3
           days.The use of short acting bronchodilator in an as-needed basis is not restricted.
           According to the Raw data determined every 8 hours, individualized dosing group will
           receive an additional 4 puffs of 25 mcg salmeterol /250 mcg fluticasone plus 4 puffs of
           fenoterol if the value is higher than personal target Raw (Once it coincides with
           regular dosing period of salmeterol/fluticasone, only fenoterol will be added). No such
           extra dose will be given to fixed dosing (control) group regardless of Raw value.

           *Statistical Analysis

        -  Student's t test will be used to compare ∆Raw of both groups. For the comparisons of
           other continuous variables without distribution normality, Wilcoxon rank sum test will
           be used. When comparing two categorical variables, Chi-square or Fisher's exact test
           will be used when appropriate. A P value of less than 0.05 is considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>∆Raw (the difference between measured and target airway resistance)</measure>
    <time_frame>Airway resistance will be recorded everyday until discontinuation of ventilator or the 28th day if ventilator-dependent</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapidity of ∆Raw change</measure>
    <time_frame>Airway resistance will be measured everyday until discontinuation of ventilator or the 28th day if ventilator-dependent</time_frame>
    <description>The slope of curve of ∆Raw over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of ventilator-free days from day 1 to 28</measure>
    <time_frame>the 28th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of breathing without assistance by day 28</measure>
    <time_frame>the 28th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of episode of nosocomial pneumonia</measure>
    <time_frame>the 28th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of total puff of rescue short-acting bronchodilator</measure>
    <time_frame>the 28th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of drug-related adverse effect</measure>
    <time_frame>28th day</time_frame>
    <description>Naranjo score should be over 4 to be considered drug-related adverse effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>the 180th day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol/fluticasone</intervention_name>
    <description>Each puff contains 25 mcg salmeterol /250 mcg fluticasone</description>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_label>Fixed dosing</arm_group_label>
    <other_name>*Advair</other_name>
    <other_name>*Seretide</other_name>
    <other_name>*Viani</other_name>
    <other_name>*Adoair</other_name>
    <other_name>*Foxair</other_name>
    <other_name>*Quikhale SF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ipatropium/salbutamol</intervention_name>
    <description>Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg</description>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_label>Fixed dosing</arm_group_label>
    <other_name>Combivent</other_name>
    <other_name>DuoNeb</other_name>
    <other_name>Breva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_label>Fixed dosing</arm_group_label>
    <other_name>Solu-Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Additional broncho-dilators inhalation</intervention_name>
    <description>Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met</description>
    <arm_group_label>Individualized dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Determining personal target airway resistance</intervention_name>
    <description>Three consecutive doses of 4, 8 and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The airway resistance measured 15 minutes later is assigned as this patient's personal target airway resistance.</description>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_label>Fixed dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ventilator support</intervention_name>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_label>Fixed dosing</arm_group_label>
    <other_name>Only AVEA (CareFusion, Yorba Linda, CA, USA) ,e500 (Newport Medical Instrument Inc. CA, USA) or Evita 4 (Drager, Lubeck, Germany) ventilator will be used.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic obstructive pulmonary disease

          -  acute respiratory failure under ventilator support for less than 72 hours

          -  endotracheal tube inserted

        Exclusion Criteria:

          -  confirmed asthma

          -  Acute Physiology and Chronic Health Evaluation II score over 35

          -  a co-morbidity of septic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin-hwar Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhua Christian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shin-hwar Wu</last_name>
    <phone>886-4-723-8595</phone>
    <phone_ext>3978</phone_ext>
    <email>126366@cch.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <state>Taiwan</state>
        <zip>50006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin-hwar Wu</last_name>
      <phone>886-4-723-8595</phone>
      <phone_ext>3978</phone_ext>
      <email>126366@cch.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Kai-huang Lin</last_name>
      <phone>886-4-723-8595</phone>
      <phone_ext>3971</phone_ext>
      <email>54407@cch.org.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Shin-hwar Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai-huang Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin-hsing Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lih-jen Shyu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fuller HD, Dolovich MB, Posmituck G, Pack WW, Newhouse MT. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients. Comparison of dose to the lungs. Am Rev Respir Dis. 1990 Feb;141(2):440-4.</citation>
    <PMID>2154154</PMID>
  </reference>
  <reference>
    <citation>Aerosol consensus statement. Consensus Conference on Aerosol Delivery. Chest. 1991 Oct;100(4):1106-9. Review.</citation>
    <PMID>1914568</PMID>
  </reference>
  <reference>
    <citation>Dhand R, Duarte AG, Jubran A, Jenne JW, Fink JB, Fahey PJ, Tobin MJ. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):388-93.</citation>
    <PMID>8756811</PMID>
  </reference>
  <reference>
    <citation>Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45.</citation>
    <PMID>7249508</PMID>
  </reference>
  <reference>
    <citation>Malliotakis P, Linardakis M, Gavriilidis G, Georgopoulos D. Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study. Crit Care. 2008;12(6):R140. doi: 10.1186/cc7117. Epub 2008 Nov 14.</citation>
    <PMID>19014570</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>September 9, 2013</last_update_submitted>
  <last_update_submitted_qc>September 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Changhua Christian Hospital</investigator_affiliation>
    <investigator_full_name>Shin-hwar Wu</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>Bronchodilator agents,</keyword>
  <keyword>chronic obstructive pulmonary disease,</keyword>
  <keyword>endotracheal intubation,</keyword>
  <keyword>mechanical ventilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Fenoterol</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

